ClinicalTrials.gg
TerminatedNCT05630937Updated Jun 19, 2025Results posted

Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy

A Phase 1/2 interventional study of NMS-01940153E in Unresectable Hepatocellular Carcinoma (HCC), sponsored by Nerviano Medical Sciences. Terminated at 9 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-19.

Sponsored by Nerviano Medical Sciences · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
In the Phase II part of the study, among the participants evaluable for efficacy, no objective (partial response or clinical response) was observed at the first futility analysis.

From the registry’s dates

  • Registered 2 years after the study started (first participant enrolled Nov 2020, registered Nov 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 206 studies in Carcinoma, Hepatocellular with a site in Italy — 49 open to participants now, 74 under way, 12 of them phase 3. Carcinoma, Hepatocellular · Italy.

Enrollment
124th of 144
31 · median 156
Started
2020
with 5 others
Phase 1/2
14 of 206
3 open now
Registered
150th of 206
by date

Among the 206 studies in Carcinoma, Hepatocellular with a site in Italy, this one is the 124th largest by enrollment of the 144 interventional ones that give a count, is one of 6 that started in 2020, is one of 14 in phase 1/2, and was the 150th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

49 of the 206 studies in Carcinoma, Hepatocellular with a site in Italy are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Carcinoma, Hepatocellular with a site in Italy, or all of them as a file.
02

Study summary

This is a Phase I/II, open-label, non-randomized, multicenter study to explore safety, tolerability and antitumor activity of NMS-01940153E as single agent in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy.

The Phase I portion is designed as a dose-escalation study in sequential cohorts of patients aimed to obtain the maximum tolerated dose (MTD) that is defined based on the dose limiting toxicities (DLTs) observed in the first cycle of treatment.

The Phase II portion is designed as a two-stage study with an interim analysis for futility and stopping criteria for unacceptable toxicity to assess the antitumor activity of NMS-01940153E in adult patients with unresectable HCC previously treated with systemic therapy measured as objective response rate.

03

Conditions studied

  • Unresectable Hepatocellular Carcinoma (HCC)

Keywords

  • Unresectable Hepatocellular Carcinoma (HCC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:

  1. Histological, cytological or radiological diagnosis of HCC, according to the American Association for the Study of Liver Diseases (AASLD) / European Association for the Study of the Liver (EASL) criteria, in subjects that are or not able to tolerate the standard therapy, or subjects for whom the standard therapy is not considered appropriate by the physician.
  2. The subject has disease that is not amenable to a curative treatment approach (e.g., transplant, surgery, radiofrequency ablation) and unsuitable for or refractory to locoregional treatments (e.g., TACE).
  3. At least one uni-dimensional by CT or MRI according to 1.1 which is either not previously treated by local therapy or, if treated, it has clearly progressed before the subject is recruited.
  4. Phase I only: subjects must have disease relapsed or refractory to the standard of care treatment not exceeding 3 lines of prior systemic treatment. Subjects intolerant to previous treatment with tyrosine kinase inhibitors (TKIs) are eligible. Phase II: subjects must have disease relapsed or refractory to the standard of care treatment including an immunocheckpoint inhibitor as and at least a tyrosine kinase inhibitor, not exceeding 3 lines of prior systemic treatment. A minimum of 14 days of treatment with prior TKI would be required to qualify as line of therapy;
  5. score ≤ 6 (class A).
  6. (ECOG) performance status of 0 or 1.
  7. Age ≥18 years old on day of consent.
  8. No history of liver transplantation or not listed for high urgent transplantation.
  9. Meets required laboratory data
  10. In case of active (HBV) or chronic infection the patient should receive antiviral therapy per local standard of care.
  11. Patients must use effective or abstinence. Female subjects must be surgically sterile or, if subjects of , must agree to use effective contraception or abstinence during the period of therapy and in the following 180 days after discontinuation of study treatment. Male subjects must be surgically sterile or must agree to use effective contraception or abstinence during the period of therapy and in the following 90 days after discontinuation of study treatment.
  12. With the exception of alopecia, resolution of all acute toxic effects of any prior systemic therapy, surgery or radiotherapy to National Cancer Institute (NCI) common terminology criteria (CTC) (Version 5.0) Grade ≤1 or to the baseline laboratory values as defined in Inclusion Criterion Number 9.
  13. Able and willing to comply with scheduled visits, therapy plans, and laboratory tests required in this protocol.
  14. Signed and dated independent ethics committee (IEC)-approved Form indicating that the subject is aware of the neoplastic nature of his/her disease and has been informed of the procedures to be followed, the nature of the therapy, potential benefits, side effects, discomforts, risks and alternative treatments.

Exclusion criteria

Exclusion Criteria:

The presence of any of the following will exclude a subject from study enrollment:

  1. Known fibrolamellar HCC or mixed hepato-cholangiocarcinoma.
  2. Subjects with untreated or incompletely treated varices with bleeding or high risk for bleeding are excluded with the following clarification: subjects with history of prior variceal bleeding must have been treated with adequate endoscopic therapy without any evidence of recurrent bleeding for at least 6 months prior to study entry and must be stable on optimal medical management (e.g. non-selective beta blocker, proton pump inhibitor) at study entry.
  3. Subjects with using Fridericia standard (QTcF) ≥480 milliseconds or with risk factors for torsade de pointes (e.g., heart failure, uncontrolled hypokalemia, family history of long QT syndrome) or receiving treatment with concomitant medications known to prolong the QT/QTc interval that cannot be replaced with another treatment.
  4. Ascites defined as Grade ≥2. Subjects who have been on a stable medication regimen for at least 2 months to manage ascites are eligible if they show ascites Grade \<2.

    Subjects with clinically undetectable ascites who are Child A with detectable ascites at CT/MRI are eligible.

  5. Uncontrolled high blood pressure (systolic blood pressure, SBP >150 mmHg and/or diastolic blood pressure, DBP >95 mmHg, despite optimal treatment, on at least 2 out of 3 determinations repeated at 30 minutes interval and done in case that the first one meets the criterion for exclusion).
  6. Direct-Acting Antivirals (DAA) at the time of treatment start; previous virus (HCV) treatment with DAAs is allowed.
  7. Clinical evidence of hepatic encephalopathy.
  8. Known or evidence of .
  9. Known history of allergic reactions to polysorbate 80.
  10. Any of the following in the past 6 months: myocardial infarction, uncontrolled cardiac arrhythmia, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or , pulmonary embolism, deep vein thrombosis (except chronic/stable portal vein thrombosis).
  11. Major surgery, other than diagnostic surgery, within 4 weeks before treatment start.
  12. Any anticancer agent within 4 weeks or, in absence of toxicity, 5 half-lives (within 6 weeks for nitrosureas, mitomycin C and liposomal doxorubicin) before treatment start.
  13. Radiation therapy within 4 weeks or radionuclide treatment (e.g., I-131 or Y-90) within 6 weeks before treatment start.
  14. Untreated uncontrolled bacterial, viral, or fungal infections including acute infection or acquired immunodeficiency syndrome (AIDS), untreated uncontrolled , untreated uncontrolled HCV, untreated uncontrolled concomitant HBV and HCV; patients who are seropositive following HBV vaccine are eligible.
  15. Subjects under treatment with therapeutic dose of anticoagulants (e.g., warfarin or warfarin-related agents, low-molecular weight heparin, or similar agent such as anti Xa and anti-thrombin agents) or antiplatelet agents (e.g. clopidogrel) or with coagulation disorders. Aspirin at dose up to 100 mg is permitted. Prophylaxis with anticoagulants is allowed to meet the (INR) value range as cited in inclusion criterion 9.
  16. Uncontrolled diabetes mellitus.
  17. Pregnant or breast-feeding women.
  18. Known second that is progressing or requiring active treatment. Exceptions include adequately treated basal cell or squamous cell skin cancer or in situ carcinoma of the cervix uteri.
  19. Current enrollment or participation in another interventional clinical trial.
  20. respiratory or metabolic diseases uncontrolled by medication.
  21. Subjects with active alcohol and/or substances abuse.
  22. Any known organ dysfunction, serious illness, acute or chronic medical or psychiatric condition, or laboratory abnormality which, in the Investigator's opinion, may increase the risk associated/interfere with study participation, or with the interpretation of the results.
  23. Subjects who, within 7 days prior to the first NMS-01940153E intake, are receiving or received strong inducers of flavin-containing monooxygenase FMO1 and FMO3.
  24. Subjects who are receiving sensitive substrates, CYP3A4 and breast cancer resistance protein (BCRP) substrates with narrow therapeutic index (NTI).
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    NMS-01940153E

    Phase I: Patients will be allocated to sequential cohorts of progressively higher dose levels of NMS-01940153E based on the presence of Dose Limiting Toxicities (DLT). Phase II: Patients will be treated at the recommended Phase II dose (RP2D) defined in the Phase I portion.

    Drug: NMS-01940153E

Interventions

  • DrugNMS-01940153E

    Route of administration: intravenous (IV) solution

06

What researchers measure

Primary outcomes

  1. Phase I Drug Related Dose Limiting Toxicities (DLTs)

    All 12 Phase I treated patients were evaluable for DLT (Dose-Limiting Toxicity Evaluable Set) and included 6 patients treated at each of the two dose levels explored (i.e., 100 mg/m2/week and 135 mg/m2/week) who received at least 66% of the study drug in the first 28-day cycle of treatment and underwent a DLT assessment within the DLT window. Participants who experienced DLTs are presented.

    Time frame: Phase I: From screening to end of first 28-day cycle (17 months)

  2. Phase II Objective Response Rate

    The objective response rate (ORR) was calculated as the proportion of evaluable patients who achieved, as best overall response (BOR), confirmed complete response (CR) or partial response (PR) measured by investigator-assessed RECIST 1.1 (Phase II).

    Time frame: Phase II: From Phase II start to Study Completion (23 months)

Secondary outcomes

  1. Treatment-emergent Adverse Events by Maximum CTC Grade

    The maximum Common Terminology Criteria (CTC) grade (graded using National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\] Version 5.0) experienced by each participant is presented. If an AE was reported for a participant more than once during treatment, the worst CTC Grade is presented here. Phase 2 started before Phase 1 completed. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4 Life-threatening consequences; urgent intervention indicated.

    Time frame: Phase I: From the Study Start Date to Phase I Completion (32 months) - Phase II: From Phase II start to Study Completion (23 months)

  2. Treatment-emergent Adverse Events Related to NMS-01940153E

    The number of treatment-emergent adverse events related to NMS-01940153E by maximum CTC grade experienced (graded using NCI CTCAE Version 5.0). Whether the the AE was related or not was assessed by the investigator. If an AE was reported for a participant more than once during treatment, the worst CTC Grade is presented. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4 Life-threatening. Phase 2 started before Phase 1 completed.

    Time frame: Phase I: From the Study Start Date to Phase I Completion (32 months) - Phase II: From Phase II start to Study Completion (23 months)

  3. Hematology: Overall Treatment-emergent Abnormalities by Dose Level and Maximum CTC Grade

    Number of treatment emergent abnormalities (at any grade) at all dose levels are presented. CTC = Common Terminology Criteria WBC = white blood cells

    Time frame: From screening to 28 days follow-up, an average 6 months

  4. Neutrophils Count Decrease: Time to First Occurrence of >=Grade 3 and Time to Recovery to Grade 1

    The mean days to first occurrence of neutrophil count decrease are presented for all dose levels. Grade 0: ≥2,000/mm3 Grade 1: ≥1,500-\< 2,000/mm3 Grade 2: ≥1,000- \< 1,500/mm3 Grade 3: ≥500- \< 1,000/mm3 Grade 4: \<500/mm3 * G3 = Time (days) to Treatment Start to First Occurrence of Neutrophil Count Decrease \>=Grade 3 * G3 to Recovery to G1 = Time (days) to First Occurrence of Neutrophil Count Decrease \>= Grade 3 to Recovery to Grade 1

    Time frame: From screening to 28 days follow-up, an average 6 months

  5. Blood Chemistry: Treatment-emergent Abnormalities by Dose Level

    Treatment-emergent abnormalities in blood chemistry at any grade are presented by dose level. ALP = Alkaline phosphatase ALT = Alanine aminotransferase AST = Aspartate aminotransferase GGT = Gamma-glutamyl transferase LDH = Lactate dehydrogenase

    Time frame: From screening to 28 days follow-up, an average 6 months

  6. Blood Chemistry and Coagulation: Treatment-emergent Abnormalities

    Treatment Emergent abnormalities by dose Level are presented for blood chemistry and coagulation parameters. INR = international normalized ratio LNL = lower normal limit NL = normal limit ULN = upper limit of normal

    Time frame: From screening to 28 days follow-up, an average 6 months

  7. Electrocardiogram Abnormalities

    The number of participants who experienced electrocardiogram abnormalities are presented.

    Time frame: From screening to 28 days follow-up, an average 6 months

  8. Tmax and Tlast of NMS-01940153E

    Plasma pharmacokinetic (PK) profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. Tmax = Time to maximum observed plasma concentration Tlast = Time of last detectable concentration

    Time frame: Day 1 to Day 15

  9. Cmax and Clast of NMS-01940153E

    Plasma pharmacokinetic (PK) profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. Cmax = Maximum observed plasma concentration Clast = Last detectable concentration

    Time frame: Day 1 to Day 15

  10. AUClast, AUCweekly, and AUCinf of NMS-01940153E

    Plasma pharmacokinetic (PK) profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. Infusions occurred on Days 1, 8, and 15. AUClast = Area under the interpolated observed plasma time-concentration curve from infusion start to the last observed plasma concentration AUCweekly = Area under the interpolated observed plasma time-concentration curve from infusion start to 168 hours AUCinf = Area under the interpolated observed plasma time-concentration curve from infusion start extrapolated to infinity based on the last observed plasma concentration

    Time frame: From Days 1 to 21 (168 hours after the Day 15 infusion)

  11. t½,z of NMS-01940153E

    Plasma pharmacokinetic (PK) profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. t½,z = Half-life of the terminal phase of observed plasma concentration

    Time frame: Day 1 to Day 15

  12. CL and CLss of NMS-01940153E

    Plasma pharmacokinetic (PK) profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. CL = Clearance based on last observed concentration and extrapolation to infinity CLss = Clearance calculated for a dosing period of 168 h either after a single dose or in steady-state

    Time frame: Day 1 to Day 15

  13. Vss and Vss,SS of NMS-01940153E

    Plasma pharmacokinetic (PK) PK profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. Vss = Volume of distribution at steady state based last observed concentration extrapolated to infinity and Clearance calculated for a dosing period of 168 h either after a single dose or in steady-state Vss,SS = Volume of distribution at steady state based last observed concentration extrapolated to infinity and clearance based on last observed concentration and extrapolation to infinity

    Time frame: Day 1 to Day 15

  14. RA AUCweekly and RA Cmax of NMS-01940153E

    Plasma pharmacokinetic (PK) PK profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. Infusions occurred on Days 1, 8, and 15. RA AUCweekly = Accumulation ratio Day 1 to 15 calculated using area under the interpolated observed plasma time-concentration curve from infusion start to 168 hours RA Cmax = Accumulation ratio Day 1 to 15 calculated using maximum observed plasma concentration

    Time frame: Day 21 (168 hours after the Day 15 infusion)

  15. FE of NMS-01940153E

    Urine pharmacokinetic profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. FE = Molar fraction of excreted compound relative to the administered molar dose calculated using urine concentration and volume data

    Time frame: Day 1 to Day 15

  16. Phase I Objective Tumor Response (Partial and Complete Response)

    Phase I any dose level, objective response and best overall tumor response are presented, as measured by investigator assessed RECIST 1.1 (Phase I). The objective response rate was calculated as the proportion of evaluable patients who achieved best overall response (BOR), confirmed complete response (CR) or partial response (PR).

    Time frame: Phase I: From the Study Start Date to Phase I Completion (32 months)

  17. Phase II Objective Response Rate as Measured by Investigator-assessed mRECIST

    Objective response rate as measured by investigator-assessed mRECIST in Phase II.

    Time frame: Phase II: From Phase II start to Study Completion (23 months)

  18. Phase I: Duration of Response (DoR) as Measured by Investigator-assessed RECIST 1.1

    Duration of response (DoR) as measured by investigator-assessed Response evaluation criteria in solid tumours (RECIST) 1.1. Duration of Response (months): was time in months from response start date to either date of disease progression/death due to progression of disease. It was calculated only for participants with complete response or partial response as best overall response.

    Time frame: Phase I: From the Study Start Date to Phase I Completion (32 months)

  19. Phase II: Duration of Response (DoR) as Measured by Investigator-assessed RECIST 1.1. and Investigator-assessed mRECIST

    Duration of response (DoR) as measured by investigator-assessed Response evaluation criteria in solid tumours (RECIST) 1.1 and investigator-assessed modified RECIST (mRECIST). Duration of Response (months): was time in months from response start date to either date of disease progression/death due to progression of disease. It was calculated only for participants with complete response or partial response as best overall response.

    Time frame: Phase II: From Phase II start to Study Completion (23 months)

  20. Progression Free Survival, as Measured by Investigator-assessed RECIST 1.1, in Phases I and II

    Progression Free Survival as measured by investigator assessed RECIST 1.1, for all treated participants in Phase I and Phase II. Phase 2 started before Phase 1 completed.

    Time frame: Phase I: From the Study Start Date to Phase I Completion (32 months) - Phase II: From Phase II start to Study Completion (23 months)

  21. Overall Survival in Phases I and II

    Overall Survival for all treated participants in Phases I and II. The estimates are based on the Kaplan-Meier (KM) method. Phase 2 started before Phase 1 completed.

    Time frame: Phase I: From the Study Start Date to Phase I Completion (32 months) - Phase II: From Phase II start to Study Completion (23 months)

07

Results

Posted May 7, 2025
Limitations and caveats
In the Phase II part of the study, among the patients evaluable for efficacy, no objective response (partial response or clinical response) was observed at the first futility analysis. Therefore, this study was terminated for clinical futility, according to the protocol rules.

Participant flow

Participant flow — Overall Study
MilestonePhase 1 Participants: 100 mg/m2/WeekPhase I Participants: 135 mg/m2/WeekPhase II Participants: 100 mg/m2/WeekEnrolled But Not Treated
Started66181
Completed5590
Not completed1191
Withdrew: Study terminated by sponsor1180
Withdrew: Lost to follow-up0010
Withdrew: Enrolled but not treated0001

Outcome measures

PrimaryPhase I Drug Related Dose Limiting Toxicities (DLTs)

All 12 Phase I treated patients were evaluable for DLT (Dose-Limiting Toxicity Evaluable Set) and included 6 patients treated at each of the two dose levels explored (i.e., 100 mg/m2/week and 135 mg/m2/week) who received at least 66% of the study drug in the first 28-day cycle of treatment and underwent a DLT assessment within the DLT window. Participants who experienced DLTs are presented.

Time frame:
Phase I: From screening to end of first 28-day cycle (17 months)
Reported as:
Count of participants · Participants
Phase I Drug Related Dose Limiting Toxicities (DLTs)
Participants100 mg/m2/Week Dose (Phase I)135 mg/m2/Week Dose (Phase I)
Phase I Drug Related Dose Limiting Toxicities (DLTs)02
PrimaryPhase II Objective Response Rate

The objective response rate (ORR) was calculated as the proportion of evaluable patients who achieved, as best overall response (BOR), confirmed complete response (CR) or partial response (PR) measured by investigator-assessed RECIST 1.1 (Phase II).

Time frame:
Phase II: From Phase II start to Study Completion (23 months)
Reported as:
Count of participants · Participants
Phase II Objective Response Rate
ParticipantsPhase II (Evaluable Population)
Stable Disease3
Progressive Disease11
Complete Response0
Partial Response0
SecondaryTreatment-emergent Adverse Events by Maximum CTC Grade

The maximum Common Terminology Criteria (CTC) grade (graded using National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\] Version 5.0) experienced by each participant is presented. If an AE was reported for a participant more than once during treatment, the worst CTC Grade is presented here. Phase 2 started before Phase 1 completed. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4 Life-threatening consequences; urgent intervention indicated.

Time frame:
Phase I: From the Study Start Date to Phase I Completion (32 months) - Phase II: From Phase II start to Study Completion (23 months)
Reported as:
Count of participants · Participants
Treatment-emergent Adverse Events by Maximum CTC Grade
Participants100 mg/m2/Week Dose (Phase I)135 mg/m2/Week Dose (Phase I)Phase II (Evaluable Population)
Grade 1003
Grade 2118
Grade 3337
Grade 4120
SecondaryTreatment-emergent Adverse Events Related to NMS-01940153E

The number of treatment-emergent adverse events related to NMS-01940153E by maximum CTC grade experienced (graded using NCI CTCAE Version 5.0). Whether the the AE was related or not was assessed by the investigator. If an AE was reported for a participant more than once during treatment, the worst CTC Grade is presented. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4 Life-threatening. Phase 2 started before Phase 1 completed.

Time frame:
Phase I: From the Study Start Date to Phase I Completion (32 months) - Phase II: From Phase II start to Study Completion (23 months)
Reported as:
Number · events
Treatment-emergent Adverse Events Related to NMS-01940153E
events100 mg/m2/Week Dose (Phase I)135 mg/m2/Week Dose (Phase I)Phase II (Evaluable Population)
Grade 1007
Grade 2113
Grade 3222
Grade 4120
SecondaryHematology: Overall Treatment-emergent Abnormalities by Dose Level and Maximum CTC Grade

Number of treatment emergent abnormalities (at any grade) at all dose levels are presented. CTC = Common Terminology Criteria WBC = white blood cells

Time frame:
From screening to 28 days follow-up, an average 6 months
Reported as:
Number · events
Hematology: Overall Treatment-emergent Abnormalities by Dose Level and Maximum CTC Grade
events100 mg/m2/Week Dose (Phase I and II)135 mg/m2/Week Dose (Phase I Only)All Treated Participants (Phase I and II; All Dose Levels)
Hemoglobin Decreased13518
Neutrophil Count Decreased6410
WBC Decreased8614
Platelet Count Decreased6410
SecondaryNeutrophils Count Decrease: Time to First Occurrence of >=Grade 3 and Time to Recovery to Grade 1

The mean days to first occurrence of neutrophil count decrease are presented for all dose levels. Grade 0: ≥2,000/mm3 Grade 1: ≥1,500-\< 2,000/mm3 Grade 2: ≥1,000- \< 1,500/mm3 Grade 3: ≥500- \< 1,000/mm3 Grade 4: \<500/mm3 * G3 = Time (days) to Treatment Start to First Occurrence of Neutrophil Count Decrease \>=Grade 3 * G3 to Recovery to G1 = Time (days) to First Occurrence of Neutrophil Count Decrease \>= Grade 3 to Recovery to Grade 1

Time frame:
From screening to 28 days follow-up, an average 6 months
Reported as:
Mean · days
Neutrophils Count Decrease: Time to First Occurrence of >=Grade 3 and Time to Recovery to Grade 1
days100 mg/m2/Week Dose (Phase I and II)135 mg/m2/Week Dose (Phase I Only)All Treated Participants (Phase I and II; All Dose Levels)
>=G363.00 ± 19.8028.00 ± 15.3639.67 ± 23.38
>= G3 to Recovery to G17.00 ± 1.417.33 ± 3.517.20 ± 2.59
SecondaryBlood Chemistry: Treatment-emergent Abnormalities by Dose Level

Treatment-emergent abnormalities in blood chemistry at any grade are presented by dose level. ALP = Alkaline phosphatase ALT = Alanine aminotransferase AST = Aspartate aminotransferase GGT = Gamma-glutamyl transferase LDH = Lactate dehydrogenase

Time frame:
From screening to 28 days follow-up, an average 6 months
Reported as:
Number · events
Blood Chemistry: Treatment-emergent Abnormalities by Dose Level
events100 mg/m2/Week Dose (Phase I and II)135 mg/m2/Week Dose (Phase I Only)All Treated Participants (Phase I and II; All Dose Levels)
Hypoalbuminemia8412
Hypoglycemia011
AST Increased12315
ALT Increased8210
GGT Increased9110
Creatinine Increased639
Blood Bilirubin Increased718
ALP Increased10111
Blood LDH Increased14418
Hypocalcemia112
Hypernatremia011
Hyperkalemia707
Hypomagnesemia538
SecondaryBlood Chemistry and Coagulation: Treatment-emergent Abnormalities

Treatment Emergent abnormalities by dose Level are presented for blood chemistry and coagulation parameters. INR = international normalized ratio LNL = lower normal limit NL = normal limit ULN = upper limit of normal

Time frame:
From screening to 28 days follow-up, an average 6 months
Reported as:
Number · events
Blood Chemistry and Coagulation: Treatment-emergent Abnormalities
events100 mg/m2/Week Dose (Phase I and II)135 mg/m2/Week Dose (Phase I Only)All Treated Participants (Phase I and II; All Dose Levels)
Hyponatremia: Total426
Hyponatremia: Below LNL426
Hypokalemia: Total011
Hypokalemia: Below LNL011
Phosphatemia: Total11213
Phosphatemia: Above ULN303
Phosphatemia: Below LNL729
Phosphatemia: Above/Below NL101
Hyperglycemia: Total9211
Hyperglycemia: Above ULN9110
Hyperglycemia: Above/Below NL011
Blood Urea Nitrogen: Total202
Blood Urea Nitrogen: Above ULN202
Urea: Total606
Urea: Above ULN505
Urea: Below LNL101
Unconjugated Bilirubin: Total303
Unconjugated Bilirubin: Above ULN303
Total Protein: Total729
Total Protein: Above ULN202
Total Protein: Below LNL426
Total Protein: Above/Below NL101
INR: Total11112
INR: Above ULN819
INR: Below LNL101
INR: Above/Below NL202
SecondaryElectrocardiogram Abnormalities

The number of participants who experienced electrocardiogram abnormalities are presented.

Time frame:
From screening to 28 days follow-up, an average 6 months
Reported as:
Count of participants · Participants
Electrocardiogram Abnormalities
Participants100 mg/m2/Week Dose (Phase I)135 mg/m2/Week Dose (Phase I)Phase II (Evaluable Population)
Electrocardiogram Abnormalities000
SecondaryTmax and Tlast of NMS-01940153E

Plasma pharmacokinetic (PK) profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. Tmax = Time to maximum observed plasma concentration Tlast = Time of last detectable concentration

Time frame:
Day 1 to Day 15
Reported as:
Mean · hours
Tmax and Tlast of NMS-01940153E
hours100 mg/m2/Week Dose (Phase I Only)135 mg/m2/Week Dose (Phase I Only)
Tmax: Day 10.933 ± 0.03271.19 ± 0.513
Tmax: Day 151.10 ± 0.2161.87 ± 1.90
Tlast: Day 1169 ± 3.01154 ± 39.2
Tlast: Day 15144 ± 48.5169 ± 0.418
SecondaryCmax and Clast of NMS-01940153E

Plasma pharmacokinetic (PK) profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. Cmax = Maximum observed plasma concentration Clast = Last detectable concentration

Time frame:
Day 1 to Day 15
Reported as:
Mean · μM
Cmax and Clast of NMS-01940153E
μM100 mg/m2/Week Dose (Phase I Only)135 mg/m2/Week Dose (Phase I Only)
Cmax: Day 10.754 ± 0.1741.91 ± 0.640
Cmax: Day 151.35 ± 1.101.59 ± 1.31
Clast: Day 10.0590 ± 0.01910.0840 ± 0.0335
Clast: Day 150.113 ± 0.04540.133 ± 0.0779
SecondaryAUClast, AUCweekly, and AUCinf of NMS-01940153E

Plasma pharmacokinetic (PK) profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. Infusions occurred on Days 1, 8, and 15. AUClast = Area under the interpolated observed plasma time-concentration curve from infusion start to the last observed plasma concentration AUCweekly = Area under the interpolated observed plasma time-concentration curve from infusion start to 168 hours AUCinf = Area under the interpolated observed plasma time-concentration curve from infusion start extrapolated to infinity based on the last observed plasma concentration

Time frame:
From Days 1 to 21 (168 hours after the Day 15 infusion)
Reported as:
Mean · h·μM
AUClast, AUCweekly, and AUCinf of NMS-01940153E
h·μM100 mg/m2/Week Dose (Phase I Only)135 mg/m2/Week Dose (Phase I Only)
AUClast: Day 120.8 ± 4.3124.8 ± 8.55
AUClast: Day 1530.0 ± 9.1639.1 ± 14.9
AUCweekly: Day 120.8 ± 4.3525.7 ± 7.11
AUCweekly: Day 1532.4 ± 6.4939.0 ± 14.8
AUCinf: Day 128.7 ± 6.8837.1 ± 14.9
AUCinf: Day 1548.1 ± 19.662.9 ± 34.1
Secondaryt½,z of NMS-01940153E

Plasma pharmacokinetic (PK) profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. t½,z = Half-life of the terminal phase of observed plasma concentration

Time frame:
Day 1 to Day 15
Reported as:
Mean · days
t½,z of NMS-01940153E
days100 mg/m2/Week Dose (Phase I Only)135 mg/m2/Week Dose (Phase I Only)
t½,z Day 13.74 ± 0.8004.17 ± 1.40
t½,z Day 154.38 ± 2.644.79 ± 1.15
SecondaryCL and CLss of NMS-01940153E

Plasma pharmacokinetic (PK) profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. CL = Clearance based on last observed concentration and extrapolation to infinity CLss = Clearance calculated for a dosing period of 168 h either after a single dose or in steady-state

Time frame:
Day 1 to Day 15
Reported as:
Mean · L/h
CL and CLss of NMS-01940153E
L/h100 mg/m2/Week Dose (Phase I Only)135 mg/m2/Week Dose (Phase I Only)
CL: Day 110.1 ± 3.1610.2 ± 4.01
CL: Day 156.12 ± 2.246.19 ± 2.08
CLss: Day 113.8 ± 4.1413.8 ± 3.73
CLss: Day 158.53 ± 2.509.31 ± 2.52
SecondaryVss and Vss,SS of NMS-01940153E

Plasma pharmacokinetic (PK) PK profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. Vss = Volume of distribution at steady state based last observed concentration extrapolated to infinity and Clearance calculated for a dosing period of 168 h either after a single dose or in steady-state Vss,SS = Volume of distribution at steady state based last observed concentration extrapolated to infinity and clearance based on last observed concentration and extrapolation to infinity

Time frame:
Day 1 to Day 15
Reported as:
Mean · L
Vss and Vss,SS of NMS-01940153E
L100 mg/m2/Week Dose (Phase I Only)135 mg/m2/Week Dose (Phase I Only)
Vss: Day 11230 ± 3951210 ± 199
Vss: Day 15787 ± 304919 ± 245
Vss,SS: Day 11700 ± 6201630 ± 285
Vss,SS: Day 151180 ± 6491380 ± 354
SecondaryRA AUCweekly and RA Cmax of NMS-01940153E

Plasma pharmacokinetic (PK) PK profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. Infusions occurred on Days 1, 8, and 15. RA AUCweekly = Accumulation ratio Day 1 to 15 calculated using area under the interpolated observed plasma time-concentration curve from infusion start to 168 hours RA Cmax = Accumulation ratio Day 1 to 15 calculated using maximum observed plasma concentration

Time frame:
Day 21 (168 hours after the Day 15 infusion)
Reported as:
Mean · ratio
RA AUCweekly and RA Cmax of NMS-01940153E
ratio100 mg/m2/Week Dose (Phase I Only)135 mg/m2/Week Dose (Phase I Only)
RA AUCweekly: Day 151.66 ± 0.1881.51 ± 0.293
RA Cmax: Day 151.78 ± 1.360.858 ± 0.547
SecondaryFE of NMS-01940153E

Urine pharmacokinetic profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. FE = Molar fraction of excreted compound relative to the administered molar dose calculated using urine concentration and volume data

Time frame:
Day 1 to Day 15
Reported as:
Mean · percentage
FE of NMS-01940153E
percentage100 mg/m2/Week Dose (Phase I Only)135 mg/m2/Week Dose (Phase I Only)
FE Day 10.458 ± 0.3740.357 ± 0.260
FE Day 150.563 ± 0.4240.826 ± 0.713
SecondaryPhase I Objective Tumor Response (Partial and Complete Response)

Phase I any dose level, objective response and best overall tumor response are presented, as measured by investigator assessed RECIST 1.1 (Phase I). The objective response rate was calculated as the proportion of evaluable patients who achieved best overall response (BOR), confirmed complete response (CR) or partial response (PR).

Time frame:
Phase I: From the Study Start Date to Phase I Completion (32 months)
Reported as:
Count of participants · Participants
Phase I Objective Tumor Response (Partial and Complete Response)
Participants100 mg/m2/Week Dose (Phase I)135 mg/m2/Week Dose (Phase I)
Objective Response (Partial Response)11
Objective Response (Complete Response)00
Stable Disease12
Progressive Disease42
SecondaryPhase II Objective Response Rate as Measured by Investigator-assessed mRECIST

Objective response rate as measured by investigator-assessed mRECIST in Phase II.

Time frame:
Phase II: From Phase II start to Study Completion (23 months)
Reported as:
Count of participants · Participants
Phase II Objective Response Rate as Measured by Investigator-assessed mRECIST
ParticipantsPhase II Treated Participants
Stable Disease3
Progressive Disease11
Objective Response (Partial Response)0
Objective Response (Complete Response)0
SecondaryPhase I: Duration of Response (DoR) as Measured by Investigator-assessed RECIST 1.1

Duration of response (DoR) as measured by investigator-assessed Response evaluation criteria in solid tumours (RECIST) 1.1. Duration of Response (months): was time in months from response start date to either date of disease progression/death due to progression of disease. It was calculated only for participants with complete response or partial response as best overall response.

Time frame:
Phase I: From the Study Start Date to Phase I Completion (32 months)
Reported as:
Number · months
Phase I: Duration of Response (DoR) as Measured by Investigator-assessed RECIST 1.1
months100 mg/m2/Week Dose (Phase I)135 mg/m2/Week Dose (Phase I)
Phase I: Duration of Response (DoR) as Measured by Investigator-assessed RECIST 1.12.69.3
SecondaryPhase II: Duration of Response (DoR) as Measured by Investigator-assessed RECIST 1.1. and Investigator-assessed mRECIST

Duration of response (DoR) as measured by investigator-assessed Response evaluation criteria in solid tumours (RECIST) 1.1 and investigator-assessed modified RECIST (mRECIST). Duration of Response (months): was time in months from response start date to either date of disease progression/death due to progression of disease. It was calculated only for participants with complete response or partial response as best overall response.

Time frame:
Phase II: From Phase II start to Study Completion (23 months)

No measurements were reported for this outcome.

SecondaryProgression Free Survival, as Measured by Investigator-assessed RECIST 1.1, in Phases I and II

Progression Free Survival as measured by investigator assessed RECIST 1.1, for all treated participants in Phase I and Phase II. Phase 2 started before Phase 1 completed.

Time frame:
Phase I: From the Study Start Date to Phase I Completion (32 months) - Phase II: From Phase II start to Study Completion (23 months)
Reported as:
Median · months
Progression Free Survival, as Measured by Investigator-assessed RECIST 1.1, in Phases I and II
months100 mg/m2/Week Dose (Phase I)135 mg/m2/Week Dose (Phase I)Phase II (Evaluable Population)
Progression Free Survival, as Measured by Investigator-assessed RECIST 1.1, in Phases I and II1.9 (1.7 to 6.5)7.8 (1.8 to 25.1)1.9 (1.8 to 4.1)
SecondaryOverall Survival in Phases I and II

Overall Survival for all treated participants in Phases I and II. The estimates are based on the Kaplan-Meier (KM) method. Phase 2 started before Phase 1 completed.

Time frame:
Phase I: From the Study Start Date to Phase I Completion (32 months) - Phase II: From Phase II start to Study Completion (23 months)
Reported as:
Median · months
Overall Survival in Phases I and II
months100 mg/m2/Week Dose (Phase I)135 mg/m2/Week Dose (Phase I)Phase II (Evaluable Population)
Overall Survival in Phases I and II9.7 (5.2 to NA)15.7 (4.7 to NA)7.3 (3.9 to NA)

Adverse events

Collected over Phase I: From the Study Start Date to Phase I Completion (32 months) - Phase II: From Phase II start to Study Completion (23 months). Phase 2 started before Phase 1 completed.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase I: 100 mg/m2/Week5/6 (83.3%)1/6 (16.7%)5/6 (83.3%)
Phase I: 135 mg/m2/Week5/6 (83.3%)2/6 (33.3%)6/6 (100%)
Phase II: 100 mg/m2/Week9/18 (50%)5/18 (27.8%)18/18 (100%)
Most frequent serious events
Most frequent serious events
EventPhase I: 100 mg/m2/WeekPhase I: 135 mg/m2/WeekPhase II: 100 mg/m2/Week
AnaemiaBlood and lymphatic system disorders0/61/60/18
NeutropeniaBlood and lymphatic system disorders0/61/60/18
SepsisInfections and infestations1/61/61/18
Device related bacteraemiaInfections and infestations1/60/60/18
Disease progressionGeneral disorders0/60/62/18
Pathological fractureMusculoskeletal and connective tissue disorders0/60/61/18
Device related infectionInfections and infestations0/60/61/18
Peritonitis bacterialInfections and infestations0/60/61/18
Most frequent other events
Showing 10 of 79
Most frequent other events
EventPhase I: 100 mg/m2/WeekPhase I: 135 mg/m2/WeekPhase II: 100 mg/m2/Week
NeutropeniaBlood and lymphatic system disorders2/63/62/18
Abdominal pain upperGastrointestinal disorders3/60/64/18
DiarrhoeaGastrointestinal disorders0/63/62/18
Pain in extremityMusculoskeletal and connective tissue disorders1/63/61/18
AstheniaGeneral disorders1/61/68/18
Infusion site reactionGeneral disorders1/62/63/18
Oedema peripheralGeneral disorders2/61/61/18
Non-cardiac chest painGeneral disorders2/60/60/18
AnaemiaBlood and lymphatic system disorders0/62/61/18
ThrombocytopeniaBlood and lymphatic system disorders0/62/62/18

Baseline characteristics

All treated participants

Age, Categorical
Age, Categorical(Participants)Phase I Participants: 100 mg/m2/WeekPhase I Treated Participants: 135 mg/m2/WeekPhase II Participants: 100 mg/m2/WeekTotal
<=18 years0000
Between 18 and 65 years331016
>=65 years33814
Sex: Female, Male
Sex: Female, Male(Participants)Phase I Participants: 100 mg/m2/WeekPhase I Treated Participants: 135 mg/m2/WeekPhase II Participants: 100 mg/m2/WeekTotal
Female1012
Male561728
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase I Participants: 100 mg/m2/WeekPhase I Treated Participants: 135 mg/m2/WeekPhase II Participants: 100 mg/m2/WeekTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American1001
White561829
More than one race0000
Unknown or Not Reported0000
Eastern cooperative oncology group performance status
Eastern cooperative oncology group performance status(participants)Phase I Participants: 100 mg/m2/WeekPhase I Treated Participants: 135 mg/m2/WeekPhase II Participants: 100 mg/m2/WeekTotal
ECOG Performance Status 0331016
ECOG Performance Status 133814
08

Study locations

9 sites
  • University of California Irvine Health
    Orange, California 92868-3201, United States
  • Siteman Cancer Center - Washington University Medical Campus
    Saint Louis, Missouri 63110-1032, United States
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Milano, 20133, Italy
  • Azienda Sanitaria Locale Napoli 1 Centro - Ospedale del Mare
    Naples, 80145, Italy
  • Istituto Oncologico Veneto - IRCCS
    Padova, 35128, Italy
  • Azienda Ospedaliero Universitaria Pisana - Ospedale Santa Chiara
    Pisa, 56126, Italy
  • Istituto Clinico Humanitas
    Rozzano, 20089, Italy
  • Azienda Ospedaliera Ordine Mauriziano di Torino
    Torino, 10128, Italy
  • Hospital Clínic de Barcelona
    Barcelona, 8036, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Jan 2024, 38 months.

Results were first posted in May 2025, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2022
First posted
Nov 30, 2022
StartActual
Nov 13, 2020
Primary completionActual
Jan 31, 2024
CompletionActual
Aug 6, 2024
Results first posted
May 7, 2025
Last update
Jun 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05630937
Lead sponsor
Nerviano Medical Sciences
Responsible party
Sponsor
First posted
Nov 30, 2022
Start date
Nov 13, 2020
Primary completion
Jan 31, 2024
Completion
Aug 6, 2024
Results posted
May 7, 2025
Last update
Jun 19, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion